Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers-Reference-Cited by-同舟云学术

Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Published:2014-07-24 Issue:9 Volume:12 Page:1428-1436
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Levi M.¹,Moore K. T.²,Castillejos C. F.²,Kubitza D.³,Berkowitz S. D.⁴,Goldhaber S. Z.⁵,Raghoebar M.⁶,Patel M. R.⁷,Weitz J. I.⁸,Levy J. H.⁷

Affiliation:

1. Academic Medical Center; University of Amsterdam; Amsterdam the Netherlands

2. Janssen Research & Development; Titusville NJ USA

3. Clinical Pharmacology; Bayer Pharma AG; Wuppertal Germany

4. Bayer HealthCare Pharmaceuticals; Montville NJ USA

5. Brigham and Women's Hospital; Boston MA USA

6. Clinical Pharmacology Unit; Janssen Research & Development; Antwerp Belgium

7. Duke University Medical Center; Durham NC USA

8. The Thrombosis and Atherosclerosis Research Institute; McMaster University; Hamilton Ontario Canada

Funder

Janssen Research & Development, LLC

Bayer HealthCare Pharmaceuticals

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.12599/fullpdf

Reference19 articles.

1. Bayer Pharma AG Xarelto ® (rivaroxaban) Summary of Product Characteristics 2013 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf

2. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism;Mavrakanas;Pharmacol Ther,2011

3. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management;Ng;Semin Hematol,2006

4. Efficacy and safety of a four-factor prothrombin complex concentrate (4F-PCC) in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study;Sarode;Circulation,2013

5. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects;Eerenberg;Circulation,2011

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage;European Journal of Medical Research;2024-04-24

2. Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma;Current Opinion in Anaesthesiology;2024-01-19

3. Antidotes to drug intoxications or drug overdoses;Antidotes to Toxins and Drugs;2024

4. Beware the counsel of the oracle;Journal of the American College of Emergency Physicians Open;2023-10

5. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants;Annals of Emergency Medicine;2023-09